Leonetti C, Zupi G, Calabresi F, Greco C
Experimental Chemotherapy Laboratory, Regina Elena Institute for Cancer Research, Rome, Italy.
Anticancer Res. 1990 Jan-Feb;10(1):45-8.
The therapeutic index of adriamycin (ADM) and cisplatin (DDP) combination versus repeated sequences of the more active drug (DDP) was investigated on a murine reticulum cell sarcoma of ovarian origin (M5) implanted i.m. in C57BL/6 mice. The antitumor efficacy of multiple cycles of DDP according to different regimens at a prefixed time (every 7 days) or at tumor regrowth was also evaluated. Our data demonstrate that the ADM-DDP combination did not improve the antitumoral efficacy of DDP as single agent, while repeated cycles of DDP led to a significant increase in the host life span. Differences in therapeutic effect were elicited by the two schedules: the regimen at a prefixed time showed a major effect on local tumor control, although the regimen at tumor regrowth was better tolerated.
在C57BL/6小鼠体内肌内接种源自卵巢的鼠网状细胞肉瘤(M5),研究了阿霉素(ADM)和顺铂(DDP)联合用药相对于重复使用更具活性的药物(DDP)的治疗指数。还评估了按照不同方案在固定时间(每7天)或肿瘤复发时多次使用DDP的抗肿瘤疗效。我们的数据表明,ADM-DDP联合用药并未提高DDP作为单一药物的抗肿瘤疗效,而重复使用DDP可显著延长宿主寿命。两种给药方案产生了不同的治疗效果:固定时间给药方案对局部肿瘤控制的效果更佳,尽管肿瘤复发时给药方案的耐受性更好。